Adaptive Biotechnologies (NASDAQ: ADPT) furnishes Q4 and full-year 2025 earnings release

Rhea-AI Filing Summary

Adaptive Biotechnologies Corporation furnished an update on its financial performance by issuing a press release covering results for the quarter and fiscal year ended December 31, 2025. The company submitted this current report to make that earnings release available to investors and attached it as Exhibit 99.1.

The press release with detailed financial figures and commentary is incorporated by reference but is expressly treated as "furnished" rather than "filed" under securities laws, which affects how it is used in certain legal contexts and other regulatory filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

False000147832000014783202026-02-052026-02-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 5, 2026

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

Washington	001-38957	27-0907024
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
1165 Eastlake Avenue East Seattle, Washington		98109
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 659-0067

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		ADPT		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On February 5, 2026, Adaptive Biotechnologies Corporation (the “Company”) issued a press release regarding the Company’s financial results for the quarter and fiscal year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release dated February 5, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		Adaptive Biotechnologies Corporation
Date: February 5, 2026		By:	/s/ Kyle Piskel
			Kyle Piskel
			Chief Financial Officer

FAQ

What did Adaptive Biotechnologies (ADPT) disclose in this 8-K filing?

Adaptive Biotechnologies furnished a press release reporting financial results for the quarter and fiscal year ended December 31, 2025. The release is attached as Exhibit 99.1 and provides detailed earnings information and commentary from management.

Which period’s results are covered in Adaptive Biotechnologies’ latest press release?

The press release covers Adaptive Biotechnologies’ financial results for the quarter and full fiscal year ended December 31, 2025. Investors can review that exhibit for revenue, earnings, and other performance details for this reporting period.

How is the Adaptive Biotechnologies (ADPT) earnings press release treated under securities laws?

The earnings press release attached as Exhibit 99.1 is deemed “furnished” rather than “filed” under the Securities Exchange Act of 1934. This distinction limits its use for certain liability provisions and incorporation into other registration statements.

Where can investors find Adaptive Biotechnologies’ detailed Q4 and 2025 results?

Investors can find detailed quarterly and full-year 2025 financial results in the press release attached as Exhibit 99.1 to the 8-K. That exhibit contains the company’s specific numbers, narrative discussion, and any non-GAAP reconciliations provided.

Who signed Adaptive Biotechnologies’ 8-K reporting year-end 2025 results?

The 8-K furnishing the press release for the quarter and year ended December 31, 2025 was signed on behalf of Adaptive Biotechnologies Corporation by Kyle Piskel, who serves as the company’s Chief Financial Officer and authorized officer for this report.